Resolution of 1-azabicyclo2.2.2octan-3-amine, 2-(diphenylmethyl)-n-2-methoxy-5-(1-methylethyl)phenylmethyl
CA 2227194 C · Owner: Pfizer Inc. · Inventors: Meltz, Morgan; Tickner, Derek L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a process for resolving 1-azabicyclo2.2.2octan-3amine, 2-(diphenylmethyl)-N-2-methoxy-5-(1-methylethyl)phenylmethyl comprising reacting 1-azabicyclo2.2.2octan-3-amine 2-(diphenylmethyl)-N-2-, methoxy-5-(1-methylethyl)phenylmethyl with 1R-(-)-10-camphorsulfonic acid in solvent capable of dissolving both of the foregoing reagents and selectively , dissolving the camphorsulfonic acid salt of the corresponding (2R 3R) , enantiomer relative to the (2S, 3S) enantiomer to form the camphorsulfonic , acid salt of (2S 3S)-1-azabicyclo2.2.2octan-3-amine, 2-(diphenylmethyl)-N- 2-methoxy-5-(1-methylethyl)phenylmethyl and then optionally hydrolyzing , such salt to obtain the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 4, 1996 and granted February 12, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 4, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 4, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.